Pharmabiz12h
US FDA grants breakthrough therapy designation to Avidity Biosciences’ delpacibart etedesiran to treat myotonic dystrophy type 1
US FDA grants breakthrough therapy designation to Avidity Biosciences’ delpacibart etedesiran to treat myotonic dystrophy type 1: San Diego Friday, May 10, 2024, 14:00 Hrs [IST] ...
Pharmabiz8h
Minghui Pharma to present phase I/II study results of MHB088C to treat patients with recurrent or metastatic solid tumors at ASCO meeting
Minghui Pharma to present phase I/II study results of MHB088C to treat patients with recurrent or metastatic solid tumors at ASCO meeting: Shanghai Friday, May 10, 2024, 18:00 Hrs ...
Pharmabiz4h
Acumen Pharma begins patient dosing in ALTITUDE-AD phase 2 trial of sabirnetug in early Alzheimer’s disease
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer’s ...
Pharmabiz11h
ENA Respiratory receives US patent covering INNA-051, a first-in-class antiviral innate immunomodulator
ENA Respiratory receives US patent covering INNA-051, a first-in-class antiviral innate immunomodulator: Melbourne, Australia Friday, May 10, 2024, 15:00 Hrs [IST] ENA Respiratory ...
Pharmabiz12h
OJSP launches Sudhamukti ayurvedic medicine for diabetes management
OJSP launches Sudhamukti ayurvedic medicine for diabetes management: Our Bureau, Mumbai Friday, May 10, 2024, 13:30 Hrs [IST] OJSP has launched Sudhamukti ayurvedic medicine, a br ...
Pharmabiz14h
Recce Pharma receives 2 patents in China for its RECCE 327 and RECCE 529 anti-infectives
Recce Pharmaceuticals Ltd, a company developing new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral ...
Pharmabiz7h
Bayer to present results from phase III OASIS 1 and 2 of elinzanetant to treat vasomotor symptoms associated with menopause at ACOG meeting
Bayer will present detailed results from the pivotal phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming ...
Pharmabiz9h
Andall Biosciences launches ovary care capsule, 23WELL
Shanghai Friday, May 10, 2024, 17:00 Hrs [IST] Andall Biosciences Inc (ABI), a renowned biotechnology company at the forefr ...
Pharmabiz18h
Experts advocate amendment to DMR Act, imposing substantial penalties for non-compliance
Experts advocate amendment to DMR Act, imposing substantial penalties for non-compliance: Nandita Vijayasimha, Bengaluru Friday, May 10, 2024, 08:00 Hrs [IST] Arogya Bharati and t ...
Pharmabiz15h
ExcellGene collaborates with Cytovance Biologics to transform large molecule biologics development and production
ExcellGene collaborates with Cytovance Biologics to transform large molecule biologics development and production: Oklahoma City Friday, May 10, 2024, 11:00 Hrs [IST] ExcellGene S ...
Pharmabiz16h
NIH to launch long Covid trials to study sleep disturbances, exercise intolerance, and post exertional malaise
NIH to launch long Covid trials to study sleep disturbances, exercise intolerance, and post exertional malaise: Bethesda, Maryland Friday, May 10, 2024, 10:00 Hrs [IST] The Nation ...
Pharmabiz12h
SEC recommends permission to SII for Omicron XBB 1.5 variant Covid-19 vaccine
A Subject Expert Committee (SEC), which advices the national drug regulator on approvals and clinical trials related to Covid-19 vaccines, has recommended grant of permission to Serum Institute of ...